Cosentyx is an injectable drug that contains sequinumab in its composition, which is used in some cases of moderate or severe plaque psoriasis to prevent the appearance of skin changes and symptoms such as itching or flaking.
This drug has in its composition a human antibody, IgG1, which is able to inhibit the function of the protein IL-17A, responsible for the formation of plaques in case of psoriasis.
- Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults seeking systemic therapy or light therapy.
The way Cosentyx is used varies by patient and type of psoriasis and should therefore always be guided by an experienced physician who specializes in the treatment of psoriasis.
The recommended dose is 300 mg, which equates to two subcutaneous injections of 150 mg, with initial administration at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance.
The recommended dose for people with psoriatic arthritis is 150 mg, by subcutaneous injection, with initial administration at weeks 0, 1, 2, 3 and 4, followed by monthly interview.
For people with an inadequate response to moderate to severe concomitant anti-TNF-alpha or plaque psoriasis, the recommended dose is 300 mg, administered in two 150 mg subcutaneous injections, with initial administration at weeks 0, 1, 2, 3 and 4. followed by monthly maintenance.
In people with ankylosing spondylitis, the recommended dose is 150 mg, administered by subcutaneous injection, with initial administration at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance.
In patients without improving symptoms until 16 weeks, discontinuation of treatment is recommended.
The most common side effects that can occur during treatment are upper respiratory tract infections with sore throat or nasal congestion, canker sores, diarrhea, hives and nasal discharge.
If the person has difficulty breathing or swallowing, if there is swelling of the face, lips, tongue or throat or severe itchy skin, with red rashes or swelling, you should consult your doctor immediately and stop treatment.
Cosentyx is contraindicated in patients with severe active infection, such as tuberculosis, for example, as well as in patients with hypersensitivity to sequinumab or any other component present in the formula.